5 Results for "

Lepodisiran

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Lepodisiran" in MCE Product Catalog:

Cat. No.: HY-177640
CAS No.: 2808361-18-2
Synonyms: LY3819469
Lepodisiran (LY3819469) is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran can be used in studies related to atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-177640A
CAS No.: 2766131-24-0
Synonyms: LY3819469 sodium
Lepodisiran (LY3819469) sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-177640C
FAM labled Lepodisiran (LY3819469) sodiumis a FAM labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-177640B
Target:  

HSV

Research Areas:  

Metabolic Disease

Lepodisiran sodium scrambled negative control is the sequence scrambled negative control of Lepodisiran sodium.
loading...
    loading...
Cat. No.: HY-177640D
Cy3 labled Lepodisiran (LY3819469) sodium is a Cy3 labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
loading...
    loading...